PsilodexMedication × psilocybin
Your list , 0 items
General prescriptions
Brand names
Felbatol
Reviewed 2026-10-04

Felbamate

An anticonvulsant reserved for severe epilepsy not controlled by other drugs; FDA-approved for partial seizures and Lennox-Gastaut syndrome.

psilodex.org/m/felbamate · data v2026.10.05

Clinical contraindication
None listed
No label contraindication covering psilocybin was found. This is not a finding that the combination has been shown to be without risk.
Psilocybin evidence
No psilocybin data
Half-life
20–23 h
Approximate, in adults. Source under Interaction below.
Named in state rules?
Not namedColorado Condition rules (3)
Not namedOregon
PendingNew Mexico
Cite asPsilodex, “Felbamate”, v2026.10.05. psilodex.org/m/felbamate

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

What it is used for

FDA status

FDA-approved

FDA-approved for
  • Partial seizures in adults (severe, refractory epilepsy)
  • Seizures of Lennox-Gastaut syndrome in children (add-on treatment)
Sources [1]
Other safety

Boxed warning: aplastic anemia, at an incidence that may be more than 100 times that of the untreated population, and acute liver failure.

About the medication itself, separate from any interaction with psilocybin.

Sources [1]

01 Interaction with psilocybin

ND

No known interaction with psilocybin; its label warns of rare aplastic anemia and liver failure. Stopping it suddenly after regular use can cause seizures.

Detail Not studied with psilocybin, and no mechanism linking them has been described. Separately, its label carries a boxed warning for aplastic anemia (failure to make blood cells) and acute liver failure. Its label also lists insomnia, dizziness and sleepiness, plus the suicidality warning given for all antiepileptic drugs. Its label notes seizure risk on sudden stopping. Sources [1]

Human data with psilocybin
No psilocybin data; based on its label
Half-life
20–23 h (FDA label, checked 2026-10-04) Longer in reduced kidney function.
Evidence types on this record
No psilocybin dataNo psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts

02 Pharmacology relevant to psilocybin

3 listed · counted on reports
Withdrawal or rebound if stopped abruptly
Stopping suddenly can cause withdrawal or a rebound of symptoms. Sources [1]
Liver injury
The label or source warns of liver injury, from raised liver enzymes to liver failure. Liver disease also affects how the body clears psilocin. Sources [1]
Psychiatric reactions
The label or source warns of psychiatric effects such as psychosis, mania, hallucinations, suicidal thoughts or severe mood or behavior changes. Psilocybin can also bring up strong emotions, so these warnings are relevant to screening. Sources [1]

03 State rules

Plain-language summary · official text governs
CO4 CCR 755-1
Not namedCondition rules (3)

No provision names this medication or its class.

Colorado · checked 2026-10-04
OROAR 333-333
Not named

No provision names this medication or its class.

Oregon · checked 2026-10-04
NM7.35.3 NMAC (proposed)
Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-10-04

04 Conditions to ask about

Screening items in state rules

This medication is usually taken for a condition. State rules screen for some conditions directly, so the medication is a prompt to ask about them. Confirm with the participant; never assume a condition from the medication.

  • Seizure disorder (usual indication)
    • CO 2.5(A)(2) · Clinical Facilitator licensees
    • CO 6.16(F)(2)(a) · Facilitators without a clinical facilitator license
    • CO 6.16(F)(1) · All licensees

05 Sources

1
  1. FELBATOL (felbamate) tablet and oral suspension · FDA label (DailyMed) — revised 2025-12 | Psychiatric reactions: WARNINGS - Suicidal Behavior and Ideation "Antiepileptic drugs (AEDs) including Felbatol®, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication." | Withdrawal or rebound if stopped abruptly: WARNINGS "Antiepileptic drugs should not be suddenly discontinued because of the possibility of increasing seizure frequency." | Liver injury: BOXED WARNING - Hepatic Failure "EVALUATION OF POSTMARKETING EXPERIENCE SUGGESTS THAT ACUTE LIVER FAILURE IS ASSOCIATED WITH THE USE OF FELBATOL®." | BOXED WARNING - Aplastic Anemia "THE USE OF FELBATOL® (felbamate) IS ASSOCIATED WITH A MARKED INCREASE IN THE INCIDENCE OF APLASTIC ANEMIA." | CLINICAL PHARMACOLOGY - Pharmacokinetics "Felbamate is excreted with a terminal half-life of 20-23 hours, which is unaltered after multiple doses."

Record history

  • v2026.10.02First published.
  • 2026-10-04Last reviewed against its sources.

Report an error in this record →

Before you startTerms 2026-10-01

What Psilodex is, and isn't.

  1. 01Psilodex summarizes published evidence and public state rules. It does not decide whether you can safely use psilocybin or take part in services, and it is not medical advice.
  2. 02Psilodex presents information only. Do not stop or change a medication without talking with the prescriber. Bring the report to them.
  3. 03Your searches and list stay in this browser and are not sent to us. Opening a medication's page is an ordinary web request, so our hosting providers see which page was opened. What we can and can't see.

In an emergency, call 911. For a mental health crisis, call or text 988. Full terms and privacy.